Printer Friendly

Thergelfas: Novel nanometrically structured therapeutic hydrogel as injectable for fascial tissues surrounding the nerves intended for preventive treatment of chronic pain.

Duration: From 2018-11-01 to 2020-10-31 ,grantagreementsigned

Total cost: Eur 170 121,60

Eu contribution: Eur 170 121,60

Objective: The key goals of the thergelfas project are: (a) the training of a talented experienced researcher in the fast growing field of innovative biomaterials for medical applications where the host and partner institutions have a critical knowledge and expertise; And, (b) the design and development of cost- efficient polymer materials in order to develop a new medicinal product for post-operative acute pain treatment and prevention of chronification.the aim of the research project and the main scientific challenge is thereby to develop a therapeutically effective hydrogel based injectable product to be applied during and post-surgery in the fascial tissue that protects the nerves where the pain originates and chronifies. Thergelfas expects to create the proof of concept of a new medicinal product by combining advanced materials (a biodegradable, Antiseptic and biocompatible carrier, Made of porous nanostructured hydrogel based on hyaluronic acid) with the ability to load and release non-steroidal antiinflamatory drugs in a controlled manner. It is aimed for the improvement of the current multimodal strategies of peripheral nerve blockade injections used during and post-surgery in acute pain treatment to prevent it from becoming chronic and that unfortunately are unsuccessful many times. The first achievement will be that of the training of the experienced researcher in new areas of knowledge such as business development from original concept stages to production scale-up, Manufacturing and marketing stages. The second achievement will be to scientifically assess whether these hydrogels can improve and replace currently used therapies, To develop a proof-of-concept scalable product. The third achievement will be to learn how to perform correctly the necessary steps needed to launch a product of this kind, Such as record and prepare all the documentation needed to present the product to the corresponding regulatory agencies.

Project completion date : 2020-10-31 12:00:00

Major organization : I+MED S.COOP. PEQUENA

Address : Albert Einstein St., 15

01510 Miano, lava

Country :Spain

Financier : EUROPEAN UNION (EU),

Financier address : European Union (Eu)

Rue De La Loi 200/Wetstraat 200,

B-1049 Bruxelles/Brussels,


Tel: 32-2-2999696, 2993085

Fax: 32-2-2961749

Url: Ec.Europa.Eu/

[c] 2018 Al Bawaba ( Provided by SyndiGate Media Inc. ( ).

COPYRIGHT 2018 SyndiGate Media Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Mena Report
Article Type:Disease/Disorder overview
Date:Oct 27, 2018
Previous Article:One Vanderbilt in New York City.
Next Article:Spirit: Scalable privacy preserving intelligence analysis for resolving identities.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters